Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 177,704 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the sale, the chief operating officer now directly owns 740,976 shares of the company’s stock, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Trading Up 2.1 %

NASDAQ:ROIV opened at $12.08 on Friday. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The firm has a market cap of $8.79 billion, a price-to-earnings ratio of 2.14 and a beta of 1.25. The company’s 50-day moving average is $11.92 and its two-hundred day moving average is $11.56.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ROIV shares. Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of ROIV. Mutual of America Capital Management LLC grew its stake in Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after acquiring an additional 1,142 shares during the period. Acadian Asset Management LLC grew its position in shares of Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares during the period. Covestor Ltd increased its stake in Roivant Sciences by 9.1% in the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after purchasing an additional 1,605 shares during the last quarter. US Bancorp DE lifted its position in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the period. Finally, Quarry LP boosted its stake in Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after buying an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.